8-Chloroadenosine for Refractory Acute Myelogenous Leukemia

Phase-Based Progress Estimates
City of Hope Medical Center, Duarte, CARefractory Acute Myelogenous Leukemia+2 More8-Chloroadenosine - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new combination therapy of 8-chloroadenosine and venetoclax to see if it is safe and effective in treating patients with acute myeloid leukemia.

Eligible Conditions
  • Refractory Acute Myelogenous Leukemia
  • Acute Myeloid Leukemia
  • Acute Recurrent Myeloid Leukemia

Treatment Effectiveness

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Up to 1 year

Year 1
Overall survival (OS)
Year 1
Event-free survival (EFS)
Year 1
Duration of response (DOR)
Day 28
Dose limiting toxicity (DLT)
Up to 1 year
Incidence of adverse events (AEs)
Time to response

Trial Safety

Trial Design

1 Treatment Group

Treatment (8-chloroadenosine, venetoclax)
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: 8-Chloroadenosine · No Placebo Group · Phase 1

Treatment (8-chloroadenosine, venetoclax)Experimental Group · 2 Interventions: 8-Chloroadenosine, Venetoclax · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
523 Previous Clinical Trials
2,249,708 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,149 Previous Clinical Trials
41,161,390 Total Patients Enrolled
Vinod PullarkatPrincipal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 16 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least three more months.
You have Acute Myeloid Leukemia (AML) and have either relapsed after treatment, not responded to prior treatments, or have not achieved complete response after two rounds of therapy. If you have AML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder, you must have failed prior treatments. If you have undergone allogeneic hematopoietic stem cell transplantation (alloHCT), you must have relapsed at least 3 months after the procedure and not have active graft versus host disease.

Frequently Asked Questions

To what extent is 8-Chloroadenosine a safe and reliable treatment for individuals?

"The data available for 8-Chloroadenosine's safety and efficacy is limited, thus it was rated a 1 on the Power team scale." - Anonymous Online Contributor

Unverified Answer

How many participants have enrolled in the research project thus far?

"Affirmative. Clinicaltrials.gov attests that this research study, which was initially posted on July 25th 2022, is currently recruiting participants. Approximately 30 patients are being called for at a single medical centre." - Anonymous Online Contributor

Unverified Answer

What are the primary goals of this research endeavor?

"This clinical trial will be evaluated over the course of a 28-day cycle. The primary outcome is to measure adverse effects, while secondary objectives include assessing time to response (defined by ELN criteria 2017) using Kaplan and Meier's product-limit method, determining duration of response according to ELN guidelines and employing Kaplan and Meier once again, as well as measuring overall survival with the same methodology." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies available in this study for participants?

"Affirmative. The information provided on clinicaltrials.gov suggests that this medical trial is actively enrolling participants and was initially posted on July 25th 2022, with its most recent update occurring on August 15th 2022. At present, the study requires 30 individuals to register from a single facility." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.